EARLY RESULTS: MEBO COVID-19 Back-to-Normal Clinical Trials

MEBO COVID-19 Back-to-Normal

EARLY RESULTS

July 2, 2021
Clinical Trial #NCT04832932
PROTOCOL #20210103MEBO

EXCERPTS FROM AURAMETRIX, "Viruses and Vaccines"

The research protocol was approved by MEBO Research IRB before it was open to the MEBO community around the world, which states the following reasons this study is being conducted,

COVID-19 vaccines were tested in clinical trials with thousands of participants before authorization, and were administered to over a billion people across the globe in the following 6 months… Vaccinated individuals were also posting their experiences on multiple social media groups created on Facebook, Reddit, Telegram and other platforms, but the groups were often removed as “proliferating false claims”. These forms of reporting are susceptible to biases and misclassifications and do not reach all vaccinated individuals, raising questions about risks of exacerbating health inequalities as well as security and privacy vulnerabilities…
https://www.medrxiv.org/content/10.1101/2021.06.28.21256779v1

Possible worsening of MEBO/PATM symptoms after vaccinations was reported by 10% of study participants.

Comparing data from the COVID-19 Back-to-Normal Clinical Trial to published data of other studies matching by ages and vaccines, indicate that the short-term effects are very similar. However, as our Principal Investigator, Irene Gabashvili, PhD, tells us in her Aurametrix blog post,

More significant differences were for less common and longer-term effects [after vaccination] including fast heartbeat, dry mouth, skin reactions and swollen lymph nodes…Possible worsening of MEBO/PATM symptoms after vaccinations was reported by 10% of study participants.

THE MEBO COMMUNITY AND COVID-19 INFECTIONS

Irene’s early results show a significant difference of MEBO group from the general population in the response to COVID-19 infection, and points out how the rate of “long-haulers,” who had long term adverse symptoms after contracting COVID-19, is close to some groups with severe genetic conditions,

Our rate is closer to some groups with severe genetic conditions

The most significant difference of MEBO group from the general population is the response to COVID-19 infection. 6 people (3 males, 3 females) out of 41 study participants experienced COVID-19 and all of them had long-term reactions. 5 out of 6 considered themselves long-haulers. The 6th person reported persistent MEBO/PATM issues post-acute COVID-19. That's 80-100% of long-haulers, ~4 times more than researchers estimate! Our rate is closer to some groups with severe genetic conditions - such as individuals with hypohidrotic ectodermal dysplasia - predisposing to bad smell from nostrils.

Community immunity (also known as herd immunity) protects everyone. We hope that MEBO/PATM community stays COVID-free and safe.

Gold JE et al. Study 2021

In her early results, Irene makes reference to a new study by Gold and his colleagues*, which argues,

...long-haulers might actually be experiencing an attack of fatigue-inducing Epstein-Barr virus (EBV, a member of herpesvirus family HHV-4) that was lying dormant in their bodies…Vaccines were shown to reactivate viruses too, in much rarer cases. As was demonstrated for Pfizer vaccine that woke up another herpes virus, chickenpox herpes-zoster (HHV-3), that causes shingles when reactivated (this happened to 1% of patients with autoimmune inflammatory rheumatic diseases). Herpes simplex (HSV-1) can be also kept in remission by a healthy immune system and can be also reactivated by COVID-19.

Irene raises the following suggestion, “MEBO and PATM symptoms could arise following an infection. Perhaps SARS-CoV-2 can reactivate the old viruses that caused these symptoms to begin with?” In fact, many sufferers in the MEBO community around the world have pointed out countless times that their difficult-to-control, long-term odor condition was originally triggered following a course of antibiotics for a serious infection. *Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021 Jun;10(6):763.

The MEBO community around the world profoundly appreciates Irene's dedication of over a decade to seeking answers to the various odor & PATM conditions of our members.

María

María de la Torre
Founder and Executive Director

A Public Charity
www.meboresearch.org
www.meboresearch.co.uk
MEBO's Blog (English)
El Blog de MEBO (español)

A EURORDIS and NORD Member Organization